![]() At 2 years, 33 eyes (24.8%) in the aflibercept group, 25 eyes (22.1%) in the bevacizumab group, and 40 eyes (31.0%) in the ranibizumab group had DR improvement no treatment group differences were identified. At 1 year, among 423 NPDR eyes, 44 of 141 (31.2%) treated with aflibercept, 29 of 131 (22.1%) with bevacizumab, and 57 of 151 (37.7%) with ranibizumab had improvement of DR severity (adjusted difference: 11.7% 95% CI, 2.9% to 20.6% P = .004 for aflibercept vs bevacizumab 8.9% 95% CI, 1.7% to 16.1% P = .01 for ranibizumab vs bevacizumab and 2.9% 95% CI, −5.7% to 11.4% P = .51 for aflibercept vs ranibizumab). Results A total of 650 participants (495 nonproliferative DR, 155 proliferative DR ) were analyzed 302 (46.5%) were women and mean (SD) age was 61 (10) years 425 (65.4%) were white. Main Outcomes and Measures Percentages with retinopathy improvement at 1 and 2 years and cumulative probabilities for retinopathy worsening through 2-year without adjustment for multiple outcomes. Interventions Random assignment to aflibercept, 2.0 mg bevacizumab, 1.25 mg ranibizumab, 0.3 mg, up to every 4 weeks through 2 years following a retreatment protocol. Participants were randomized in 2012 through 2013, and the trial concluded on September 23, 2015. Retinopathy improvement and worsening were determined during 2 years of treatment. ![]() Objective To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME.ĭesign, Setting, and Participants Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab. It is unknown whether these effects differ across anti-VEGF agents. ![]() Importance Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Cumulative Probability of Retinopathy Worsening Among Eyes With Moderately Severe or Severe Non-Proliferative Diabetic Retinopathy at Baseline Percentage With Improvement of Retinopathy Among Eyes With Moderately Severe or Severe Non-Proliferative Diabetic Retinopathy at BaselineĮFigure 2. Number of Anti-VEGF Injections Administered to Manage Center-Involved DME by Baseline Diabetic Retinopathy Status and Diabetic Retinopathy Improvement OutcomeĮFigure 1. Diabetic Retinopathy Worsening: Percentage With 2 or More Steps Worsening on Photos at Annual Visits by Anti-VEGF Treatment Group and Retinopathy StatusĮTable 8. Distribution of the First Event Which Triggered Categorization as Worsening of Diabetic Retinopathy by Baseline Diabetic Retinopathy StatusĮTable 7. Diabetic Retinopathy Improvement or Worsening by Anti-VEGF Treatment Group Combining NPDR and PDR SubgroupsĮTable 6. Diabetic Retinopathy Improvement: Percentage With 2 or More Steps Improvement on Photos at Annual Visits by Anti-VEGF Treatment Group and Baseline Retinopathy StatusĮTable 5. Sensitivity Analysis of Retinopathy Improvement or Worsening at 2 Years by Anti-VEGF Treatment Group and Baseline Diabetic Retinopathy StatusĮTable 4. Baseline Characteristics for Eyes Within Each Treatment Group That Completed the 1-Year and 2-Year Visit by Baseline Retinopathy SubgroupĮTable 3. Visit Completion and Availability of Gradable Photographs for Study Eyes by Baseline Retinopathy Status (Non-Proliferative Diabetic Retinopathy or Proliferative Diabetic Retinopathy) and Drug AssignmentĮTable 2. ![]() Warrier is a board-certified Vitreoretinal surgeon who specializes in overall comprehensive management of both medical and surgical disorders of the vitreous and retina.ETable 1. Vitreoretinal Surgeon Retina Specialist in Fort Myersĭr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |